JFL Life Sciences logo

JFL Life Sciences

JFLLIFE NSE
₹10.75 0.50 (4.88%)
Market Cap
₹70.94 Cr
P/E
10.44

Key Fundamentals

SMEPharmaceuticalsHealthcare
Market Cap
₹70.94 Cr
P/E (TTM)
10.44
EBITDA
₹11.80 Cr
Return on Equity
13.95%
Debt to Equity
0.48
Book Value
₹13.90
EPS (TTM)
₹1.03
52W High
₹14.70
52W Low
₹8.55

Price-based figures as of 13 Oct 2026, 14:20 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,770.7035.134,24,850 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,285.0084.272,46,488 Cr14.710.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,642.9072.891,76,601 Cr21.000.82%12.16%9.06%15,391 Cr2,156 Cr
Zydus Life Science
₹1,132.5025.201,12,967 Cr4.170.09%16.99%19.24%28,515 Cr4,593 Cr
Laurus Labs
₹2,059.40101.751,11,272 Cr21.000.10%16.38%19.67%7,323 Cr1,090 Cr
Cipla
₹1,329.6031.851,07,413 Cr3.121.00%11.21%14.88%28,786 Cr3,356 Cr
Dr Reddys Laboratories
₹1,240.0032.121,03,500 Cr2.720.67%10.87%13.94%34,555 Cr3,184 Cr
Mankind Pharma
₹2,372.0047.9597,974 Cr6.010.04%11.70%13.78%15,074 Cr2,067 Cr
Aurobindo Pharma
₹1,684.6026.2896,928 Cr2.560.24%9.25%13.58%35,390 Cr3,711 Cr
Lupin
₹1,953.6016.1589,336 Cr3.980.92%23.79%28.42%30,017 Cr5,552 Cr
JFL Life Sciences (this company)
₹10.7510.4471 Cr0.772.44%13.95%20.10%131 Cr7 Cr
Median 11 companies₹1,770.7032.121,07,413 Cr4.170.67%13.79%17.94%28,515 Cr3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-12
v2.0.0
59 Good
Overall score
Data confidence 100/100

Category scores

Quality Average 50
Returns, margins, earnings quality 22%
Valuation Strong 74
Cheap vs sector & own history 24%
Growth Strong 94
Sales & profit trajectory 9%
Financial Health Poor 37
Solvency, leverage, coverage 9%
Momentum Good 59
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 64.0% CAGR over last 5 years
  • Company's working capital requirements have reduced from 136 days to 103 days

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 12.2% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
9
Neutral
6
Bullish
4

Moving Averages

BearishNeutralBullish

Bearish

Bearish
7
Neutral
0
Bullish
3

Growth Rate

Revenue Growth
60.17% higher than 3Y

change over 1 year

Net Income Growth
52.38% higher than 3Y

change over 1 year

Cash Flow Change
-21.63%

change over 1 year

EBITDA Margin Change
-10.4%

change over 1 year Operating margin 18.83% · Jun 2026

Quarterly Results

Particulars Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
21.7
9.54
39.51
21.25
11.73
11.59
29.91
26.84
63.05
11.1
Expenses
20.15
6.48
37.1
19.9
10.35
9.66
27
23.49
59.54
9.01
Operating Profit
1.55
3.06
2.41
1.35
1.38
1.93
2.91
3.35
3.51
2.09
OPM %
7.14%
32.08%
6.1%
6.35%
11.76%
16.65%
9.73%
12.48%
5.57%
18.83%
Other Income
0.02
0
0
0
0
0
0.01
0.01
0.04
0.02
Interest
0.09
0.26
0.27
0.2
0.33
0.24
0.44
0.38
1.03
0.3
Depreciation
0.11
0.24
0.24
0.16
0.36
0.26
0.27
0.27
0.27
0.32
PBT
1.37
2.56
1.9
0.99
0.69
1.43
2.21
2.71
2.25
1.49
Tax %
13.14%
25.39%
23.16%
25.25%
86.96%
48.25%
10.86%
25.09%
26.22%
25.5%
Net Profit
1.19
1.91
1.45
0.74
0.08
0.75
1.97
2.02
1.66
1.11
EPS (₹)
0.18
0.29
0.22
0.11
0.01
0.11
0.3
0.31
0.25
0.17
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
32
30
33
34
43
47
82
131
131
Expenses
30
28
31
28
39
42
74
120
119
Operating Profit
1
2
2
5
4
5
8
12
12
OPM %
4.2%
6%
7%
16%
9%
10%
10%
9%
9%
Other Income
0
0
0
1
2
1
0
0
0
Interest
1
1
1
2
1
1
1
2
2
Depreciation
0
0
0
0
0
0
1
1
1
PBT
0
0
1
4
4
4
6
9
9
Tax %
28%
29%
27%
26%
25%
13%
32%
26%
—
Net Profit
0
0
1
3
3
3
4
6
7
EPS (₹)
1.25
1.5
1.5
0.59
0.43
0.5
0.63
0.97
1.03
Div. Payout %
0%
0%
0%
0%
0%
8%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.42
0.42
0.5
8
11
11
33
33
Reserves
5
5
6
3
21
25
6
13
Borrowings
8
9
17
16
7
6
11
22
Other Liabilities
3
10
5
21
10
15
22
39
Total Liabilities
16
24
29
48
49
57
72
106
Fixed Assets
2
5
6
7
7
12
12
15
CWIP
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
Other Assets
14
19
23
41
42
44
60
92
Total Assets
16
24
29
48
49
57
72
106
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-3
3
-6
2
-9
8
-4
-4
Investing
-1
-3
-2
-1
1
-6
0
-4
Financing
4
0
7
-1
8
-2
4
9
Net Cash Flow
0
0
0
0
0
0
0
1
Free Cash Flow
-4
0
-8
1
-9
2
-4
-8
CFO/OP
-225
177
-268
41
-206
185
-31
-37
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
111
153
132
215
192
197
155
148
Inventory Days
21
52
72
212
130
149
128
110
Days Payable
18
122
58
218
76
92
98
93
Cash Conversion Cycle
115
83
146
208
246
254
186
165
Working Capital Days
62
7
74
117
221
181
124
103
ROCE %
—
12%
10%
23%
15%
11%
16%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view JFL Life Sciences insights

58 extracted metrics + investor summaries across FY19–FY27.

Log in — free

Shareholding Pattern

Promot.67.47%Others4.22%Public28.31%As ofJun 2026

Documents

Frequently Asked Questions about JFL Life Sciences

What does JFL Life Sciences Ltd do?
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
Where is JFL Life Sciences Ltd (JFLLIFE) listed?
JFL Life Sciences Ltd trades as JFLLIFE on the NSE.
Which sector does JFL Life Sciences Ltd belong to?
JFL Life Sciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of JFL Life Sciences Ltd?
JFL Life Sciences Ltd has a market capitalisation of ₹70.94 Cr as of 13 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of JFL Life Sciences Ltd?
JFL Life Sciences Ltd trades at a PE ratio of 10.44 as of 13 Oct 2026, on earnings per share of ₹1.03, against a book value of ₹13.9 per share.
What is the 52-week high and low of JFL Life Sciences Ltd?
Over the last 52 weeks JFL Life Sciences Ltd has traded between ₹8.55 and ₹14.7 as of 13 Oct 2026.
Does JFL Life Sciences Ltd pay dividends?
JFL Life Sciences Ltd has a dividend yield of 2.44%.
What is the Return on Equity (ROE) of JFL Life Sciences Ltd?
JFL Life Sciences Ltd reported a return on equity of 13.95%. Its debt-to-equity ratio is 0.48.

Company Information

Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]

Website jfllifesciences.com
Listed 2022-09-08
Face Value ₹ 10
Shares Outstanding 6,59,90,646

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JFLLIFE.md for JFL Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List